

BSE SENSEX  
 28,183

 S&P CNX  
 8,711

Motilal Oswal values your support in the Asiamoney Brokers Poll 2016 for India Research, Sales and Trading team. We [request your ballot](#).



Click here to vote

Bloomberg	CLGT IN
Equity Shares (m)	272.0
M.Cap.(INRb)/(USDb)	227.2 / 3.4
52-Week Range (INR)	1033 / 788
1, 6, 12 Rel. Per (%)	4/3/0
12M Avg Val (INR M)	336
Free float (%)	49.0

**Financials & Valuations (INR b)**

Y/E Mar	2016	2017E	2018E
Net Sales	38.0	42.8	49.1
EBITDA	9.5	10.2	13.1
PAT	6.1	6.2	8.1
EPS (INR)	22.3	22.8	29.9
Gr. (%)	8.7	2.2	31.1
BV/Sh (INR)	37.5	41.7	45.2
RoE (%)	67.9	57.7	68.9
RoCE (%)	67.0	56.6	67.6
P/E (x)	45.5	44.5	33.9
P/BV (x)	27.1	24.4	22.5

Estimate change

TP change

Rating change

**CMP: INR1,016 TP: INR1,190(+17%)**
**Buy**
**Aggression in terms of new launches, advertising heartening**

- **Colgate-Palmolive (CLGT) posted net sales growth of 8.9% YoY (est. of 9.5%)** to INR10.1b (Ind-AS). Adjusting for excise impact YoY, organic sales growth was 12.5% YoY, led by 6% volume growth, including exports and 5% domestic volume growth (est. of +4.5%; highest in the past five quarters), selective price increases and product mix changes. EBITDA was up 3.7% YoY (est. of +19.6%) to INR2.11b, mainly because of higher A&P YoY, while Adj. PAT was up 1.3% YoY (est. of +20.8% YoY) to INR1.26b.
- **Toothpaste market share improved 60bp sequentially** to 55.9%, while toothbrushes share rose 100bp to 46.8%. New launches introduced include Colgate Sensitive Clove, a formulation of clove oil and potassium nitrate, as well as Colgate Cibaca Vedshakti with six natural ingredients.
- **Gross margin continued to show strong growth of 140bp YoY** (est. of 70bp YoY) to 62.3%. This was offset by a sharp increase in advertising spends (+ 190bp YoY despite a high base in 1QFY16) and higher staff costs (+40bp YoY). EBITDA margin declined 100bp YoY (est. of +180bp) to 20.9%. EBITDA was up 3.7% YoY (est. of +19.6%) to INR2.11b, while Adj. PAT was up 1.3% YoY (est. of +20.8% YoY) to INR1.26b.
- **Valuation and view:** We are encouraged by the pace of new launches in the herbal/non-herbal space as well as the advertising intensity. While this may affect near-term margins, it augurs well for volume growth recovery and market share growth. Oral care category has high growth potential, and Colgate has strong moats in the form of distribution, category development efforts, brand strength, R&D and advantages of concentrated focus in oral care. It also has a remarkable track record in warding off competition because of these moats. Long-term earnings growth potential is strong and balance sheet is best of breed. Changes to the model have resulted in 4% decline/3% upgrade to FY17/FY18 EPS. Maintain **Buy** with a revised target price of INR1,190 (38x June 2018 EPS, 15% premium to average multiple for the past three years).

**Quarterly Performance**

Y/E March	FY16	FY17				FY16	FY17E	(INR Million)	
		1Q	2QE	3QE	4QE			FY17	1QE Var. (%)
<b>Toothpaste Volume Gr %</b>	<b>2.0</b>	<b>5.0</b>	<b>5.5</b>	<b>6.5</b>	<b>5.5</b>	<b>2.3</b>	<b>5.5</b>	<b>4.5</b>	
<b>Net Sales</b>	<b>9,237</b>	<b>10,056</b>	<b>10,726</b>	<b>10,555</b>	<b>11,431</b>	<b>38,016</b>	<b>42,768</b>	<b>10,982</b>	<b>-8.4%</b>
YoY Change (%)	8.9	13.0	14.0	13.9	-3.9	-3.9	12.5	9.5	
<b>COGS</b>	<b>3,641</b>	<b>3,822</b>	<b>4,129</b>	<b>4,044</b>	<b>4,445</b>	<b>14,953</b>	<b>16,439</b>	<b>3,957</b>	<b>-3.4%</b>
<b>Gross Profit</b>	<b>5,596</b>	<b>6,234</b>	<b>6,598</b>	<b>6,511</b>	<b>6,986</b>	<b>23,063</b>	<b>26,329</b>	<b>7,025</b>	
Gross Margin (%)	60.6	62.0	61.5	61.7	61.1	60.7	61.6	64.0	
<b>Other operating Expenses</b>	<b>3,630</b>	<b>4,197</b>	<b>3,974</b>	<b>3,990</b>	<b>4,402</b>	<b>14,051</b>	<b>16,562</b>	<b>4,684</b>	
% to sales	39.3	41.7	37.0	37.8	38.5	37.0	38.7	42.6	
<b>Other operating Income</b>	<b>72</b>	<b>76</b>	<b>67</b>	<b>85</b>	<b>231</b>	<b>451</b>	<b>458</b>	<b>72</b>	
<b>EBITDA</b>	<b>2,038</b>	<b>2,113</b>	<b>2,691</b>	<b>2,606</b>	<b>2,815</b>	<b>9,463</b>	<b>10,225</b>	<b>2,414</b>	<b>-12.5%</b>
Margins (%)	21.9	20.9	24.9	24.5	24.1	24.6	23.7	21.8	
YoY Growth (%)		3.7	10.0	17.7	22.3	15.1	8.1	19.6	
<b>Depreciation</b>	<b>253</b>	<b>316</b>	<b>310</b>	<b>339</b>	<b>348</b>	<b>1,114</b>	<b>1,313</b>	<b>291</b>	
<b>Interest</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	
<b>Financial other Income</b>	<b>81</b>	<b>101</b>	<b>108</b>	<b>106</b>	<b>47</b>	<b>246</b>	<b>362</b>	<b>89</b>	
<b>PBT</b>	<b>1,866</b>	<b>1,897</b>	<b>2,489</b>	<b>2,373</b>	<b>2,515</b>	<b>8,595</b>	<b>9,274</b>	<b>2,213</b>	<b>-14.3%</b>
<b>Tax</b>	<b>626</b>	<b>640</b>	<b>821</b>	<b>783</b>	<b>816</b>	<b>2,325</b>	<b>3,061</b>	<b>730</b>	
Rate (%)	33.5	33.7	33.0	33.0	32.4	27.1	33.0	33.0	
<b>Adj PAT</b>	<b>1,241</b>	<b>1,257</b>	<b>1,668</b>	<b>1,590</b>	<b>1,699</b>	<b>6,270</b>	<b>6,214</b>	<b>1,482</b>	<b>-15.2%</b>
YoY Change (%)		1.3	6.3	12.9	16.5	12.2	-0.9	20.8	

E: MOSL Estimates

Krishnan Sambamoorthy (Krishnan.Sambamoorthy@MotilalOswal.com); +91 22 3982 5428

Vishal Punmiya (Vishal.Punmiya@MotilalOswal.com); +91 22 3980 4261

Investors are advised to refer through important disclosures made at the last page of the Research Report.

 Motilal Oswal research is available on [www.motilaloswal.com](http://www.motilaloswal.com)/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

## Key Quarterly Charts

Exhibit 1: Toothpaste volumes grew 5% in 1QFY17




Exhibit 2: Toothpaste volume market share stood at 55.9%





Exhibit 3: Toothbrush market share stood at 46.8%



### Valuation and view


- We are encouraged by the pace of new launches in the herbal and non-herbal space as well as the advertising intensity. While this may affect near term margins, it augurs well for volume growth recovery and market share growth. Oral care category has high growth potential and Colgate has strong moats in the form of distribution, category development efforts, brand strength, R&D and advantages of concentrated focus in oral care.
- It also has a remarkable track record in warding off competition because of these moats. Long term earnings growth potential is strong and balance sheet is best of breed.
- Changes to the model have resulted in 4% decline/3 upgrade to FY17/FY18EPS. Maintain Buy with revised target price of INR1,190 (38xJune 2018 EPS, 15% premium to average multiple for the past 3 years).

## Exhibit 4: We upgrade FY18 EPS by 3%

	Old		New		Change (%)	
	FY17E	FY18E	FY17E	FY18E	FY17E	FY18E
Sales	45,712	52,529	42,768	49,143	(6.4)	(6.4)
EBITDA	10,633	12,827	10,225	13,118	(3.8)	2.3
EPS	6,483	7,873	6,214	8,144	(4.2)	3.4


Source: Company, MOSL

## Exhibit 5: CLGT P/E (x)



Source: Bloomberg, Company, MOSL

## Exhibit 6: Colgate P/E premium vs. Sensex



Source: Bloomberg, Company, MOSL

## Exhibit 1: Valuation Matrix of coverage universe

Company	Reco	Price (INR)	Mkt Cap (USD M)	EPS Growth YoY (%)			P/E (x)			EV/EBITDA (x)			ROE (%)		Div. (%)	
				FY16	FY17E	FY18E	FY16	FY17E	FY18E	FY16	FY17E	FY18E	FY16	FY17E	FY18E	FY16
<b>Consumer</b>																
Asian Paints	Neutral	1,149	16,494	25.0	20.1	16.3	62.0	51.6	44.4	41.5	34.4	29.5	34.4	34.4	0.8	0.8
Britannia	Buy	3,152	5,658	41.9	21.6	15.2	46.5	38.3	33.2	31.8	26.5	22.0	54.6	54.6	0.8	
<b>Colgate</b>	<b>Buy</b>	<b>1,016</b>	<b>4,137</b>	<b>8.7</b>	<b>2.2</b>	<b>31.1</b>	<b>45.5</b>	<b>44.5</b>	<b>33.9</b>	<b>28.9</b>	<b>26.7</b>	<b>20.7</b>	<b>67.9</b>	<b>1.1</b>		
Dabur*	Neutral	293	7,716	17.5	12.3	15.5	41.1	36.6	31.7	33.1	29.5	25.5	33.2	33.2	0.7	
Emami*	Buy	1,149	3,904	17.7	10.0	23.9	45.6	41.5	33.5	38.9	32.3	26.7	43.4	43.4	0.7	
Godrej Consumer	Neutral	1,571	8,004	24.4	22.9	25.8	47.3	38.5	30.6	35.1	29.5	24.3	23.4	23.4	0.6	
GSK Consumer	Neutral	6,305	3,968	20.7	4.6	9.9	37.6	36.0	32.8	27.6	26.3	23.3	30.7	30.7	1.0	
Hind. Unilever	Neutral	929	30,089	12.9	7.1	12.8	48.8	45.6	40.4	34.1	31.7	28.1	82.4	82.4	1.7	
ITC	Buy	250	45,162	-3.5	17.9	15.6	32.4	27.5	23.8	20.6	18.2	15.6	29.3	29.3	2.7	
Jyothy Labs	Buy	290	785	24.2	-6.7	12.4	33.2	35.6	31.6	25.5	22.7	20.1	19.2	19.2	1.4	
Marico*	Neutral	300	5,791	26.1	14.6	22.8	53.5	46.7	38.0	36.8	32.6	26.7	36.9	36.9	1.1	
Nestle	Neutral	6,852	9,887	-7.3	-5.5	25.5	57.2	60.5	48.2	40.3	35.2	28.0	40.9	40.9	0.7	
Page Industries	Buy	14,172	2,366	21.0	25.0	31.3	66.6	53.3	40.6	41.5	33.8	26.1	46.9	46.9	0.6	
Parag Milk Foods	Neutral	324	341	-66.7	41.1	32.5	48.2	34.1	25.8	18.0	16.3	13.3	19.5	19.5	0.0	
Pidilite Inds.	Buy	729	5,594	46.6	23.0	18.2	49.1	39.9	33.8	31.0	25.8	21.7	30.4	30.4	0.6	
P&G Hygiene	Buy	6,695	3,252	19.8	12.0	19.7	52.5	46.8	39.1	35.1	30.2	24.5	31.2	31.2	1.0	
Radico Khaitan	Buy	91	180	-2.6	14.7	21.0	14.0	12.2	10.1	9.9	8.6	7.4	9.3	9.3	1.1	
United Spirits	Buy	2,238	4,867	LP	21.1	50.8	72.3	59.7	39.6	33.5	31.6	23.7	36.7	36.7	0.0	
<b>Retail</b>																
Jubilant Foodworks	Buy	1,208	1,185	-6.0	54.0	46.1	75.8	49.2	33.7	28.2	20.5	15.2	14.1	14.1	0.2	
Shopper's Stop	Neutral	382	470	19.3	48.9	30.9	65.6	44.0	33.6	15.6	12.9	10.6	6.3	6.3	0.0	
Titan Company	Neutral	420	5,575	-13.4	11.4	21.0	52.2	46.9	38.7	43.2	35.6	29.1	21.3	21.3	0.6	

Note: For Nestle FY16 means CY15

Source: Company, MOSL

## Financials and Valuations

Income Statement		(INR Million)						
Y/E March	2012	2013	2014	2015	2016	2017E	2018E	2019E
<b>Net Sales</b>	<b>26,239</b>	<b>30,841</b>	<b>35,449</b>	<b>39,548</b>	<b>38,016</b>	<b>42,768</b>	<b>49,143</b>	<b>55,728</b>
Change (%)	18.2	17.5	14.9	11.6	-3.9	12.5	14.9	13.4
COGS	10,502	12,502	14,020	14,677	14,953	16,439	18,711	21,054
<b>Gross Profit</b>	<b>15,736</b>	<b>18,339</b>	<b>21,429</b>	<b>24,871</b>	<b>23,063</b>	<b>26,329</b>	<b>30,432</b>	<b>34,674</b>
Gross Margin (%)	58.2	57.8	59.6	62.4	60.0	60.9	61.3	61.7
Operating expenses	10,645	12,568	15,128	16,920	14,051	16,562	17,779	19,821
Other Operating Income	781	897	484	340	451	458	465	472
<b>EBITDA</b>	<b>5,872</b>	<b>6,668</b>	<b>6,785</b>	<b>8,290</b>	<b>9,463</b>	<b>10,225</b>	<b>13,118</b>	<b>15,325</b>
Change (%)	11.4	13.6	1.8	22.2	14.1	8.1	28.3	16.8
Margin (%)	21.7	21.0	18.9	20.8	24.6	23.7	26.4	27.3
Depreciation	393	437	508	750	1,114	1,313	1,445	1,520
Financial Other Income	434	399	358	264	246	362	483	585
<b>Profit before Taxes</b>	<b>5,883</b>	<b>6,630</b>	<b>6,636</b>	<b>7,804</b>	<b>8,595</b>	<b>9,274</b>	<b>12,155</b>	<b>14,390</b>
Change (%)	13.1	12.7	0.1	17.6	10.1	7.9	31.1	18.4
Margin (%)	22.4	21.5	18.7	19.7	22.6	21.7	24.7	25.8
Tax	1,372	1,766	1,683	2,009	2,325	3,061	4,011	4,749
Tax Rate (%)	24.1	25.1	26.1	28.4	29.3	33.0	33.0	33.0
<b>Adjusted PAT</b>	<b>4,464</b>	<b>4,967</b>	<b>4,906</b>	<b>5,590</b>	<b>6,079</b>	<b>6,214</b>	<b>8,144</b>	<b>9,641</b>
Change (%)	10.9	11.3	-1.2	13.9	8.7	2.2	31.1	18.4
Margin (%)	17.0	16.1	13.8	14.1	16.0	14.5	16.6	17.3
Non-rec. (Exp)/Income	0	0	492	0	-313	0	0	0
<b>Reported PAT</b>	<b>4,464</b>	<b>4,967</b>	<b>5,399</b>	<b>5,590</b>	<b>5,765</b>	<b>6,214</b>	<b>8,144</b>	<b>9,641</b>

Note: We have adjusted FY16, FY17 and FY18 P&L numbers for Ind AS Impact. Since Ind AS Balance Sheet has not been shared we have retained earlier numbers.

Balance Sheet		(INR Million)						
Y/E March	2012	2013	2014	2015	2016	2017E	2018E	2019E
Share Capital	272	272	272	272	272	272	272	272
Reserves	4,082	4,624	5,727	7,431	9,923	11,065	12,035	13,281
<b>Net Worth</b>	<b>4,354</b>	<b>4,896</b>	<b>5,999</b>	<b>7,703</b>	<b>10,195</b>	<b>11,337</b>	<b>12,307</b>	<b>13,553</b>
Deferred Liability	-121	-224	-178	26	217	217	217	217
<b>Capital Employed</b>	<b>4,233</b>	<b>4,671</b>	<b>5,821</b>	<b>7,729</b>	<b>10,412</b>	<b>11,554</b>	<b>12,525</b>	<b>13,770</b>
Gross Block	6,132	6,735	9,927	12,829	15,773	18,773	19,773	20,773
Less: Accum. Depn.	-3,587	-3,929	-4,368	-5,013	-5,691	-7,004	-8,450	-9,970
<b>Net Fixed Assets</b>	<b>2,544</b>	<b>2,807</b>	<b>5,559</b>	<b>7,816</b>	<b>10,081</b>	<b>11,769</b>	<b>11,323</b>	<b>10,803</b>
Capital WIP	694	1,020	1,415	1,412	784	784	784	784
Investments	471	471	371	371	301	301	301	301
<b>Curr. Assets, L&amp;A</b>	<b>7,466</b>	<b>8,546</b>	<b>7,364</b>	<b>7,420</b>	<b>8,270</b>	<b>8,818</b>	<b>11,410</b>	<b>14,395</b>
Inventory	2,177	1,853	2,257	2,522	2,927	3,343	3,716	4,175
Account Receivables	873	812	547	696	1,015	1,146	1,317	1,494
Cash & Bank	3,098	4,288	2,870	2,545	2,883	2,797	4,713	6,919
Others	1,318	1,593	1,690	1,657	1,445	1,532	1,664	1,808
<b>Curr. Liab. and Prov.</b>	<b>6,942</b>	<b>8,172</b>	<b>8,889</b>	<b>9,290</b>	<b>9,025</b>	<b>10,117</b>	<b>11,294</b>	<b>12,512</b>
Account Payables	3,690	4,666	5,100	5,144	5,519	6,136	6,913	7,777
Other Liabilities	2,179	2,510	2,837	2,874	2,399	2,519	2,645	2,777
Provisions	1,073	995	952	1,272	1,106	1,463	1,736	1,958
<b>Net Current Assets</b>	<b>524</b>	<b>374</b>	<b>-1,525</b>	<b>-1,870</b>	<b>-755</b>	<b>-1,300</b>	<b>116</b>	<b>1,882</b>
<b>Application of Funds</b>	<b>4,233</b>	<b>4,671</b>	<b>5,821</b>	<b>7,729</b>	<b>10,412</b>	<b>11,554</b>	<b>12,525</b>	<b>13,770</b>

E: MOSL Estimates

## Financials and Valuations

### Ratios

Y/E March	2012	2013	2014	2015	2016	2017E	2018E	2019E
<b>Basic (INR)</b>								
EPS	<b>16.4</b>	<b>18.3</b>	<b>18.0</b>	<b>20.6</b>	<b>22.3</b>	<b>22.8</b>	<b>29.9</b>	<b>35.4</b>
Cash EPS	17.9	19.9	19.9	23.3	26.4	27.7	35.3	41.0
BV/Share	16.0	18.0	22.1	28.3	37.5	41.7	45.2	49.8
DPS	12.0	13.5	13.4	12.5	11.0	16.0	21.0	24.8
Payout %	73.2	73.6	74.5	60.6	49.1	70.0	70.0	70.0
<b>Valuation (x)</b>								
P/E	61.9	55.7	56.3	49.5	45.5	44.5	33.9	28.7
Cash P/E	56.9	51.2	51.1	43.6	38.4	36.7	28.8	24.8
EV/Sales	10.4	8.8	7.7	6.9	7.2	6.4	5.5	4.8
EV/EBITDA	46.5	40.7	40.3	33.0	28.9	26.7	20.7	17.6
P/BV	63.5	56.5	46.1	35.9	27.1	24.4	22.5	20.4
Dividend Yield (%)	1.2	1.3	1.3	1.2	1.1	1.6	2.1	2.4
<b>Return Ratios (%)</b>								
RoE	108.9	107.4	90.1	81.6	67.9	57.7	68.9	74.6
RoCE	113.5	111.6	93.5	82.5	67.0	56.6	67.6	73.3
RoIC	-1,009.4	-820.9	16,067.6	236.5	119.9	84.6	108.6	148.1
<b>Working Capital Ratios</b>								
Debtor (Days)	12	9	5	6	8	8	8	8
Asset Turnover (x)	8.6	9.7	8.8	6.7	4.1	4.1	4.3	4.4
<b>Leverage Ratio</b>								
Debt/Equity (x)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

### Cash Flow Statement

	(INR Million)							
Y/E March	2012	2013	2014	2015	2016	2017E	2018E	2019E
OP/(loss) before Tax	5,872	6,668	6,785	8,290	9,463	10,225	13,118	15,325
Int./Div. Received	-434	-399	-358	-264	-246	-362	-483	-585
Interest Paid	30	0	0	0	0	0	0	0
Direct Taxes Paid	-1,372	-1,766	-1,683	-2,009	-2,325	-3,061	-4,011	-4,749
(Incr)/Decr in WC	-770	1,339	480	20	-777	459	500	439
<b>CF from Operations</b>	<b>3,327</b>	<b>5,842</b>	<b>5,224</b>	<b>6,037</b>	<b>6,115</b>	<b>7,261</b>	<b>9,124</b>	<b>10,431</b>
(Incr)/Decr in FA	-904	-930	-3,587	-2,898	-2,316	-3,000	-1,000	-1,000
<b>Free Cash Flow</b>	<b>2,422</b>	<b>4,913</b>	<b>1,637</b>	<b>3,139</b>	<b>3,799</b>	<b>4,261</b>	<b>8,124</b>	<b>9,431</b>
(Pur)/Sale of Investments	-84	0	100	0	70	0	0	0
<b>CF from Invest.</b>	<b>-988</b>	<b>-930</b>	<b>-3,487</b>	<b>-2,898</b>	<b>-2,246</b>	<b>-3,000</b>	<b>-1,000</b>	<b>-1,000</b>
Change in Equity	15	-149	-75	-38	484	0	-526	-526
(Incr)/Decr in Debt	-1	0	0	0	0	0	0	0
Dividend Paid	-3,965	-4,276	-4,221	-3,848	-3,758	-5,072	-6,647	-7,869
Others	754	702	1,140	422	-256	725	966	1,170
<b>CF from Fin. Activity</b>	<b>-3,197</b>	<b>-3,723</b>	<b>-3,156</b>	<b>-3,464</b>	<b>-3,530</b>	<b>-4,347</b>	<b>-6,208</b>	<b>-7,226</b>
<b>Incr/Decr of Cash</b>	<b>-858</b>	<b>1,190</b>	<b>-1,418</b>	<b>-325</b>	<b>339</b>	<b>-86</b>	<b>1,917</b>	<b>2,205</b>
Add: Opening Balance	3,956	3,098	4,288	2,870	2,545	2,883	2,797	4,713
<b>Closing Balance</b>	<b>3,098</b>	<b>4,288</b>	<b>2,870</b>	<b>2,545</b>	<b>2,883</b>	<b>2,797</b>	<b>4,713</b>	<b>6,918</b>

E: MOSL Estimates


0

## Corporate profile

### Company description

Colgate-Palmolive India (CLGT) is the market leader in the toothpaste segment, with a share of ~56.7%. Oral Care is one of the most under-penetrated segments of the FMCG market, with ~83% of sales from toothpastes. CLGT has presence in toothbrushes and mouthwash, and Personal Care products like body wash.

### Exhibit 1: Sensex rebased



### Exhibit 2: Shareholding pattern (%)

	Jun-16	Mar-16	Jun-15
Promoter	51.0	51.0	51.0
DII	8.3	18.3	5.1
FII	16.3	6.0	20.7
Others	24.4	24.7	23.2

Note: FII Includes depository receipts

Source: Capitaline

### Exhibit 3: Top holders

Holder Name	% Holding
Life Insurance Corporation Of India	4.7
Arisaig Partners (Asia) Pte Ltd. A/c Arisaig India Fund Limited	3.4

Source: Capitaline

### Exhibit 4: Top management

Name	Designation
M V Deoras	Chairman
Vinod Nambiar	Chairman
P K Ghosh	Deputy Chairman
R A Shah	Vice Chairman
I Bachaalani	Managing Director
Godfrey Nthunzi	Whole Time Director & CFO
N Ghate	Whole-time Director & CS

Source: Capitaline

### Exhibit 5: Directors

Name	Name
Indu Shahani	J K Setna
V S Mehta	Shyamala Gopinath

\*Independent

### Exhibit 6: Auditors

Name	Type
Price Waterhouse	Statutory

Source: Capitaline

### Exhibit 7: MOSL forecast v/s consensus

EPS (INR)	MOSL forecast	Consensus forecast	Variation (%)
FY17	22.8	23.9	-4.5
FY18	29.9	27.8	7.4

Source: Bloomberg

NOTES

## Disclosures

This document has been prepared by Motilal Oswal Securities Limited (hereinafter referred to as Most) to provide information about the company (ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not constrict to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOST) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.

MOST and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that MOST and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business . The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on twin parameters of performance & profitability of MOST.

MOST generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOST generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. MOST and its affiliated company(ies), their directors and employees and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of MOST even though there might exist an inherent conflict of interest in some of the stocks mentioned the research report Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition MOST has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOST or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOST or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOST or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOST's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOST and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOST and/or its affiliates from doing so. MOST or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.

Most and its associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Most and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report

MOST and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1 % at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, MOST has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Motilal Oswal Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH000000412

Pending Regulatory inspections against Motilal Oswal Securities Limited:

SEBI pursuant to a complaint from client Shri C.R. Mohanraj alleging unauthorized trading, issued a letter dated 29th April 2014 to MOSL notifying appointment of an Adjudicating Officer as per SEBI regulations to hold inquiry and adjudicate violation of SEBI Regulations; MOSL replied to the Show Cause Notice whereby SEBI granted us an opportunity of Inspection of Documents. Since all the documents requested by us were not covered we have requested to SEBI vide our letter dated June 23, 2015 to provide pending list of documents for inspection.

List of associate companies of Motilal Oswal Securities Limited -[Click here to access detailed report](#)

### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOST research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

### COLGATE PALMOLIVE (IND)

■ Analyst ownership of the stock	No
■ Served as an officer, director or employee	No

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com) and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOST & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:** This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

### For U.S

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons.

This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

### For Singapore

Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time.

In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:

Varun Kumar  
[Varun.kumar@motilaloswal.com](mailto:Varun.kumar@motilaloswal.com)

Contact: (+65) 68189232

Office Address:21 (Suite 31),16 Collyer Quay,Singapore 04931

Kadambari Balachandran  
[kadambari.balachandran@motilaloswal.com](mailto:kadambari.balachandran@motilaloswal.com)

(+65) 68189233 / 65249115



**Motilal Oswal Securities Ltd**

Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025

Phone: +91 22 3982 5500 E-mail: [reports@motilaloswal.com](mailto:reports@motilaloswal.com)